False-positive rates in screening for trisomies 18 and 13: a comparison between first-trimester combined screening and a cfDNA-based approach.
Karl Oliver KaganJiri SonekAndreas SrokaHarald AbelePhilipp WagnerNatalia ProdanMarkus HoopmannPublished in: Archives of gynecology and obstetrics (2018)
In conclusion, the addition of screening for trisomies 18 and 13 to screening for trisomy 21 does not significantly change FPR. This is true for both the FTCS and the US-cfDNA-based approach.
Keyphrases